MP-L and GP-L are phenotypically defined as CD34− AML, positive for myeloid markers (CD13+CD33+CD117+/−); and differ by their expression of HLA-DR (≥20% for MP-L and <20% for GP-L). This evidence concerns the gene KIT and acute myeloid leukemia.